Peter Hovstadius är ny medicinsk chef på Lif

Läkaren Peter Hovstadius har utsetts till Chief Medical Officer på branschorganisationen Lif – de forskande läkemedelsföretagen.

Nya turer kring Nykodes ledning – drar tillbaka avhoppen

Norska Nykode Therapeutics får tillbaka de delar av ledningen som tidigare aviserade att de lämnar bolaget.

Automated dispensing of liquids

Have a look at how you can do easier and faster dispensing on the fly adapted to your needs

Här är de bäst säljande läkemedlen 2023

Läkemedel från MSD, Abbvie och Novo Nordisk toppar när de läkemedel som sålde för mest förra året listas.

Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...

An increasing number of people are falling ill with TBE – “Much more research is needed”

Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Över...

Artificial intelligence in radiology – “Risk prediction is very exciting”

A growing number of solutions based on artificial intelligence are being developed and used in healthcare. According to Sophia Zackrisson, Professor of Radiolog...

Ossiform: Quality control of 3D printed bone implants

Ossiform chose the GOM Scan 1.

Partial court victory for entrepreneur who lost his company

Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...

Automated dispensing

Are you interested in automated dispensing of liquids?

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

Lonza

Varningen: Risker med Mysimba inte klarlagda

De långsiktiga kardiovaskulära riskerna med viktläkemedlet Mysimba är inte helt utredda. Därför införs nu rekommendationer till hälso- och sjukvården om årlig bedömning.

Universitetssjukhusen bildar allians – ska stärka framtidens vård

Den högspecialiserade vården, forskningen och utbildningen behöver stärkas i Sverige anser samtliga sju universitetssjukhus som nu går samman i vad de kallar ”e...

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

ZEISS Insights: Measurement of bone plates and screws

Get free access to technical paper.

Beta-blockers are often given unnecessarily, a study finds – “This will affect future practice”

Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

Study: Popular diabetes treatment is not associated with thyroid cancer

Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by a...

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

Quality Assurance for the Highest Medical Standards

Metrology Solutions for Medical Components.

Fetmaläkemedlet Wegovy oroar livsmedelsföretag – ”De är rädda”

Novo Nordisks vd Lars Fruergaard Jørgensen uppger att han har fått telefonsamtal från chefer i livsmedelssektorn som ser det aptitdämpande läkemedlet Wegovy som ett hot.

De ska ge regeringen råd om life science

En rådgivande grupp bestående av experter från akademin, industrin och hälso- och sjukvården har nu utsetts. Gruppens syfte är att bistå Regeringskansliets life...

Kandidat nådde inte mål – nedskrivning hotar Karolinska Development

Investmentbolaget Karolinska Developments partner Organon har meddelat att de avslutar det kliniska utvecklingsprogrammet med läkemedelskandidaten OG-6219 efter...